Pulmonary Fibrosis News and Research

RSS

Researchers reveal why no level of air pollution is safe for respiratory health

A review in the Journal of Clinical Investigation shows how particulate matter damages the lungs through oxidative stress, inflammation, and immune disruption. It links air pollution to asthma, COPD, lung cancer, infections, and millions of premature deaths, with no safe exposure threshold.

9 Sep 2025

New technology could make MRI scanners cost-effective and more accessible

Revolutionary new technology could make MRI scanners cost effective, more widely available to local communities and help save lives, thanks to a pioneering collaboration between the University of Sheffield and GE HealthCare.

8 Sep 2025

Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF)

Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced that it has been selected by Calluna Pharma to support its Phase 2 AURORA study.

27 Aug 2025

Engineered telomerase RNA offers temporary boost to telomere length in human stem cells

Much the way the caps on the ends of a shoelace prevent it from fraying, telomeres - regions of repetitive DNA sequences and a protein structure - protect the tips of chromosomes from damage.

14 Aug 2025

New drug discovery platform aims to deliver first-in-class therapies

65LAB has awarded US$1.5 million (approx. S$1.9 million) to Professor Enrico Petretto to advance a breakthrough drug discovery platform developed at Duke-NUS Medical School. The project aims to deliver first-in-class antifibrotic therapies for lung and kidney diseases-conditions that currently have no effective treatment.

14 Aug 2025

Study investigates aging-related mechanisms in idiopathic pulmonary fibrosis using AI approaches

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by the excessive accumulation of extracellular matrix components, leading to a gradual decline in lung function and, ultimately, respiratory failure.

13 Aug 2025

Breakthrough approaches enhance RNA delivery while minimizing inflammation

Lipid nanoparticles (LNPs) are tiny fat bubbles that are used to deliver medicines, genes, and RNA into cells. However, in some cases LNPs can cause harmful inflammation as a result of the process of RNA delivery.

11 Aug 2025

Double lung transplant patient completes 32-mile Manhattan walk

Just one year after receiving a lifesaving double lung transplant, a 58-year-old Cobble Hill resident accompanied and encouraged by his care team from Rusk Rehabilitation at NYU Langone Hospital—Brooklyn met his personal goal of completing "The Great Saunter," a one-day, 32-mile walk tracing the perimeter of Manhattan that is organized by the nonprofit environmental group Shorewalkers.

4 Aug 2025

New 3D tissue model offers hope for scleroderma treatment

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and sometimes fatal illness stiffens and scars tissue in organs like the lungs, liver, and kidneys, as well as skin.

22 Jul 2025

AI reshapes ARDS care by predicting risk, guiding ventilation, and personalizing treatment

Artificial intelligence and machine learning are transforming acute respiratory distress syndrome (ARDS) management, enabling earlier detection, precision risk stratification, and tailored therapies. Emerging AI techniques promise to improve outcomes, but real-world clinical validation and integration remain critical challenges.

21 Jul 2025

New 3D bio-printed model closely mimics the complexity of natural lung tissue

UBC Okanagan researchers have developed a 3D bio-printed model that closely mimics the complexity of natural lung tissue, an innovation that could transform how scientists study lung disease and develop new treatments.

15 Jul 2025

Blocking Epac1 protein slows lung fibrosis in preclinical models

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung-scarring disease.

15 Jul 2025

Targeting SRSF7 offers potential therapy for pulmonary fibrosis

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

10 Jul 2025

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.

17 Jun 2025

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

15 Jun 2025

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial. The highest dose group demonstrated a trend toward increased forced vital capacity, especially among patients not receiving standard antifibrotic therapy, supporting further clinical investigation.

4 Jun 2025

Pulmonary Fibrosis News and Research

Researchers reveal why no level of air pollution is safe for respiratory health

New technology could make MRI scanners cost-effective and more accessible

Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF)

Engineered telomerase RNA offers temporary boost to telomere length in human stem cells

New drug discovery platform aims to deliver first-in-class therapies

Study investigates aging-related mechanisms in idiopathic pulmonary fibrosis using AI approaches

Breakthrough approaches enhance RNA delivery while minimizing inflammation

Double lung transplant patient completes 32-mile Manhattan walk

New 3D tissue model offers hope for scleroderma treatment

AI reshapes ARDS care by predicting risk, guiding ventilation, and personalizing treatment

New 3D bio-printed model closely mimics the complexity of natural lung tissue

Blocking Epac1 protein slows lung fibrosis in preclinical models

Targeting SRSF7 offers potential therapy for pulmonary fibrosis

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

New cryogenic mass spectrometry approach reveals inner structure of lipid nanoparticles

Integrating phytomedicine and nanotechnology in managing COVID-19 related heart disease

Rare lung cell found to protect against COVID-19 death

Tulane researchers identify a potential new way to treat idiopathic pulmonary fibrosis

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News